Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

In a related development, the launch of Mylan’s generic glatiramer acetate is roiling the MS therapy market. The two doses — 20 mg and the new 40 mg — have already taken about 15 percent of the combined sales of Teva’s Copaxone and Sandoz‘s Glatopa.

Sales of Glatopa, which is available only in 20 mg doses, have been most affected. Health insurers appear to prefer the generics because they’re cheaper, neurologists said.

One reason that Copaxone sales have held up better than Glatopa’s is that some neurologists said they were able to persuade health insurers or pharmacies not to switch to a generic.

https://multiplesclerosisnewstoday.com/2017/12/15/use-of-multiple-sclerosis-therapy-ocrevus-continues-to-rise/